Experienced in BRCA Positive Breast Cancer

Dr. Lainie P. Martin

Oncology
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in BRCA Positive Breast Cancer
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lainie Martin is an Oncologist in Philadelphia, Pennsylvania. Dr. Martin is rated as an Experienced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma. Dr. Martin is currently accepting new patients.

Her clinical research consists of co-authoring 66 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Temple University School Of Medicine
Residency
Boston Medical Center
Specialties
Oncology
Licenses
Specialist in PA
Board Certifications
Medical Oncology, 2006
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Languages Spoken
English
Gender
Female
Awards
Recognized annually in Philadelphia magazine's Top Docs issue from 2020 through 2025

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Jordan Center for Gynecologic Cancers
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other, Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride
Study Phase: Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Fostamatinib, Paclitaxel
Study Phase: Phase 1
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: March 26, 2024
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Antibody as a Single Agent and in Combination With Balstilimab, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Solid Tumors
A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Antibody as a Single Agent and in Combination With Balstilimab, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 03, 2022
Intervention Type: Drug
Study Phase: Phase 1
VM110 in Detection of Microscopic Tumors: A Phase I Study
VM110 in Detection of Microscopic Tumors: A Phase I Study
Enrollment Status: Terminated
Publish Date: April 07, 2020
Intervention Type: Combination product
Study Phase: Phase 1
Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients With Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse
Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients With Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse
Enrollment Status: Completed
Publish Date: July 11, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

66 Total Publications

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Journal: Gynecologic oncology
Published: May 12, 2025
Similar Doctors
Distinguished in BRCA Positive Breast Cancer
Dr. Angela R. Bradbury
Oncology
Distinguished in BRCA Positive Breast Cancer
Dr. Angela R. Bradbury
Oncology

Rena Rowan Breast Center

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Angela Bradbury is an Oncologist in Philadelphia, Pennsylvania. Dr. Bradbury is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, and Ovarian Cancer. Dr. Bradbury is currently accepting new patients.

Distinguished in BRCA Positive Breast Cancer
Dr. Susan M. Domchek
Oncology
Distinguished in BRCA Positive Breast Cancer
Dr. Susan M. Domchek
Oncology

Rena Rowan Breast Center

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susan Domchek is an Oncologist in Philadelphia, Pennsylvania. Dr. Domchek is rated as an Elite provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Domchek is currently accepting new patients.

Advanced in BRCA Positive Breast Cancer
Dr. Payal D. Shah
Oncology
Advanced in BRCA Positive Breast Cancer
Dr. Payal D. Shah
Oncology

Rena Rowan Breast Center

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Payal Shah is an Oncologist in Philadelphia, Pennsylvania. Dr. Shah has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, BRCA Positive Breast Cancer, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Martin's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile